Collplant Biotechnologies Ltd cash flow statement

In fiscal 2025, Collplant Biotechnologies Ltd's operations generated −$9.4m of cash; it spent $28,000 on capital projects, leaving free cash flow of −$9.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Collplant Biotechnologies Ltd: cash flow statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−1	−6	−4	3	−14	−3	−14	−9
Depreciation and amortisation	0	1	1	1	1	1	1	1
Stock-based pay	1	1	2	2	2	2	2	1
Capital spending	1	1	0	1	1	1	0	0
Free cash flow	−2	−7	−5	1	−15	−4	−15	−9
Free cash flow after stock pay	−3	−8	−7	−1	−17	−6	−16	−10
Shares issued	—	—	—	0	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CLGN vs KRRO CLGN vs VTGN CLGN vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Collplant Biotechnologies Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Collplant Biotechnologies Ltd.